Some chemicals in our environment act like fake hormones, tricking the brain's control center during early childhood and puberty. Imagine a thermostat that gets broken during installation; the house never reaches the right temperature. This work creates a way to spot these 'broken thermostats' using simple biological markers and computer models without needing invasive tests.
Companies struggle to predict how complex mixtures of chemicals affect human development without relying on slow, expensive, and often inaccurate animal tests.
A suite of in silico permeability models, organ-on-chip HP axis models, and a list of 13 validated EDCs for risk assessment.
If you are a drug discovery firm dealing with safety testing for pediatric medicines — this project developed organ-on-chip models and computational toxicology that allow you to predict how chemical mixtures affect the brain-pituitary axis. This reduces the need for animal testing while increasing safety accuracy.
If you are a diagnostics company dealing with a lack of early detection tools for hormonal disorders — this project developed non-invasive biomarkers based on DNA methylation patterns. This allows for the creation of screening tests to identify children at risk from chemical exposure.
If you are a product manufacturer dealing with strict chemical safety regulations for sensitive populations — this project developed a method to identify 13 specific endocrine disruptors and their mixtures. This helps you reformulate products to ensure they do not interfere with child development.
Based on available project data, no pricing or cost structures for the resulting tools or biomarkers have been disclosed.
The project uses organ-on-chip and in silico models, which are generally more scalable than traditional animal models, though specific industrial scale-up data is not provided.
Based on available project data, there is no specific information regarding the licensing terms or patent status of the biomarkers and models.
The project focuses on risk assessment of endocrine disruptors, which directly impacts compliance with environmental health and chemical safety regulations for sensitive populations.
The project period runs from 2024-01-01 to 2028-12-31, suggesting that final validated tools will be available toward the end of 2028.
The consortium is heavily research-oriented, consisting of 8 universities and 4 research institutes, with a modest industrial presence of 2 companies (14% ratio). This suggests the project is currently focused on high-level scientific validation and tool creation rather than immediate commercial rollout, though the inclusion of SMEs indicates a path toward market application.
Contact Fundacio Eurecat in Spain for technical inquiries regarding HP axis organoids.
Contact us to connect with the HYPIEND consortium for early access to biomarker data.
